11/07/2024 8:09 PM | Lantern Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
07/26/2024 3:15 PM | KEYSER D JEFFREY (Reporting) Lantern Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/17/2024 3:30 PM | Lantern Pharma (Issuer) Silberstein David S. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/17/2024 3:30 PM | Bhatia Kishor G. (Reporting) Lantern Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/17/2024 3:30 PM | Chandru Vijay (Reporting) Lantern Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/17/2024 3:30 PM | Lantern Pharma (Issuer) Margrave David R. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/17/2024 3:30 PM | KEYSER D JEFFREY (Reporting) Lantern Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
|
07/17/2024 3:30 PM | Lantern Pharma (Issuer) Maccecchini Maria-Luisa (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
07/17/2024 3:30 PM | Lantern Pharma (Issuer) SHARMA PANNA (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/10/2024 11:16 PM | Lantern Pharma (Filer)
| Form EFFECT | |
05/24/2024 3:06 PM | Lantern Pharma (Filer)
| Form S-3 Registration statement under Securities Act of 1933 | |
05/24/2024 3:08 PM | Lantern Pharma (Filer)
| Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
05/03/2024 6:30 AM | Lantern Pharma (Filer)
| Form ARS | |
04/29/2024 6:30 AM | Lantern Pharma (Filer)
| Form DEF 14A | |
04/26/2024 8:36 PM | BIOS Fund I, LP (Reporting) Lantern Pharma (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
04/26/2024 8:38 PM | BIOS Fund I QP, LP (Reporting) Lantern Pharma (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
04/26/2024 8:39 PM | BIOS Fund II, LP (Reporting) Lantern Pharma (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
04/26/2024 8:40 PM | BIOS Fund II QP, LP (Reporting) Lantern Pharma (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
04/26/2024 8:41 PM | BIOS Fund II NT, LP (Reporting) Lantern Pharma (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
02/29/2024 8:54 PM | BP Directors, LP (Reporting) Cavu Advisors, LLC (Reporting) Cavu Management, LP (Reporting) Kreis Leslie W. (Reporting) Lantern Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/29/2024 8:54 PM | BIOS Advisors GP, LLC (Reporting) BIOS Capital Management, LP (Reporting) Bios Equity Partners II, LP (Reporting) Bios Equity Partners, LP (Reporting) BIOS Fund I QP, LP (Reporting) BIOS Fund I, LP (Reporting) BIOS Fund II NT, LP (Reporting) BIOS Fund II QP, LP (Reporting) BIOS Fund II, LP (Reporting) Fletcher Aaron G.L. (Reporting) Lantern Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/28/2024 8:40 PM | BIOS Fund II, LP (Reporting) Lantern Pharma (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
02/28/2024 8:41 PM | BIOS Fund II NT, LP (Reporting) Lantern Pharma (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
02/28/2024 8:41 PM | BIOS Fund II QP, LP (Reporting) Lantern Pharma (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/19/2024 3:30 PM | BP Directors, LP (Reporting) Cavu Advisors, LLC (Reporting) Cavu Management, LP (Reporting) Kreis Leslie W. (Reporting) Lantern Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/19/2024 3:31 PM | BIOS Advisors GP, LLC (Reporting) BIOS Capital Management, LP (Reporting) Bios Equity Partners II, LP (Reporting) Bios Equity Partners, LP (Reporting) BIOS Fund I QP, LP (Reporting) BIOS Fund I, LP (Reporting) BIOS Fund II NT, LP (Reporting) BIOS Fund II QP, LP (Reporting) BIOS Fund II, LP (Reporting) Fletcher Aaron G.L. (Reporting) Lantern Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/01/2023 5:00 AM | BP Directors, LP (Reporting) Cavu Advisors, LLC (Reporting) Cavu Management, LP (Reporting) Kreis Leslie W. (Reporting) Lantern Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/01/2023 5:01 AM | BIOS Advisors GP, LLC (Reporting) BIOS Capital Management, LP (Reporting) Bios Equity Partners II, LP (Reporting) Bios Equity Partners, LP (Reporting) BIOS Fund I QP, LP (Reporting) BIOS Fund I, LP (Reporting) BIOS Fund II NT, LP (Reporting) BIOS Fund II QP, LP (Reporting) BIOS Fund II, LP (Reporting) Fletcher Aaron G.L. (Reporting) Lantern Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/01/2023 5:02 AM | Bios Equity Partners, LP (Filed by) Lantern Pharma (Subject)
| Form SC 13D/A | |
11/24/2023 3:05 PM | Lantern Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |